Demand Drivers: Increasing Prevalence of Diabetes: The growing global prevalence of type 2 diabetes is a major factor driving the demand for GLP-1 receptor agonists
Suitable for all adults
In practice, this means that their effective dosage is known, and it is precisely understood who, when, and in what quantity they can help
10.1371/journal.pone.0061822 156
Taebi M, Kariman N, Montazeri A, Alavi Majd H
Key Points The glucose-lowering, insulin-sensitizing agent metformin works mainly by reducing gluconeogenesis and opposing glucagon-mediated signalling in the liver and, to a lesser extent, by increasing glucose uptake in skeletal muscle The primary site of metformin action is the mitochondrion The antihyperglycaemic effect of metformin is probably owing to defective protein kinase A signalling Metformin affects lipid metabolism primarily via 5-AMP-activated protein kinase (AMPK) activation Antitumourigenic effects of metformin, which require further study, might be partially due to systemic metabolic alterations, including the reduced availability of insulin In cancer cells, metformin acts as an inducer of energetic stress
